Nestle cow milk protein
Under the partnership, DBV will offer its exclusive worldwide commercialization rights of DBV's diagnostic tool to Nestle.
Nestlé will make an upfront payment of €10m. DBV will be in charge of development stages, including industrialization and regulatory submissions.
It will also qualify for receiving development milestones and sales milestones and royalty payments on sales, if approved.
CMPA is a condition which is believed to be difficult to diagnose and affects up to 2-3% infants and young children during thier developmental stages, the company stated.
DBV will use its proprietary Viaskin technology platform to develop a ready-to-use, standard atopy patch test.
In 2015, Nestlé introduced the cow's milk-related symptom score (CoMiSS) awareness tool developed by international experts to assist healthcare professionals for early identification and assessment of symptoms which could be associated with CMPA in infants and young children.
The latest DBV's patch-test will facilitate early and accurate diagnosis of the condition thereby resulting in early nutrition involvement.
Nestlé Health Science CEO Greg Behar said: "This innovation can become the breakthrough diagnostic for CMPA. Early diagnosis and nutritional intervention helps get infants happily back on the path of healthy development, alleviate the anxieties of parents, and reduce healthcare costs.
"Our reach in the field of pediatric allergy makes Nestlé Health Science an ideal commercialization partner for DVB's innovative diagnostic patch. This collaboration is another step in our strategy of advancing the role of nutrition through science-based innovation."
DBV Technology CEO Dr. Pierre-Henri Benhamou said: "Combining DBV's innovative and proprietary technology with Nestlé Health Science's global presence and expertise in nutritional therapies is a synergistic approach that we believe has the potential to improve the overall health of our patients."
